{
  "docId": "019dd923-622c-750b-8b9a-2a2468219173",
  "docSlug": "ce565b841c40",
  "documentTitle": "Nevro Corp. (NVRO)",
  "authorId": "58_Scorpion_Capital",
  "authorName": "Kir Kahlon",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2021-01-07 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 164,
  "pageCount": 239,
  "prevPage": 163,
  "nextPage": 165,
  "slideType": "expose_contradiction",
  "function": "expose_contradiction",
  "density": "overcrowded",
  "nDataPoints": 2,
  "notes": "Includes two direct quotes from KOLs and a screenshot of a ClinicalTrials.gov study design page.",
  "elementsJson": [
    "headline_text",
    "paragraph",
    "quote_block",
    "screenshot"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9a-2a2468219173/164",
  "deckHref": "/decks/019dd923-622c-750b-8b9a-2a2468219173",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-2a2468219173.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-2a2468219173#slide-164",
  "components": [
    {
      "bbox": {
        "h": 0.1,
        "w": 0.33,
        "x": 0.61,
        "y": 0.8
      },
      "kind": "callout",
      "text": "SENZA-PDN study began enrollment in July 2017 per ClinicalTrials.gov, but didn't complete enrollment until Aug 2019 per Nevro press release on 8/28/19.",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "938bcce8-772d-4ff6-b86b-c26393bdbdb4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "callout",
      "text": "KOL’s indicated that it took Nevro years to complete enrollment for the PDN study, which should have been instantaneous given the vast number of diabetics in the US.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-3f3d-76db-b344-656d34e9c722",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.45,
        "x": 0.06,
        "y": 0.77
      },
      "kind": "image",
      "text": "ClinicalTrials.gov study design snippet",
      "attrs": null,
      "subkind": "screenshot",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dc7f5b7e-4c11-48a0-96e3-d34fbe9837f0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.88,
        "x": 0.06,
        "y": 0.13
      },
      "kind": "paragraph",
      "text": "KOL's indicated that it took Nevro years to complete enrollment for the PDN study, which should have been instantaneous given the vast number of diabetics in the US. Indeed, Nevro's own PDN addressable market slide indicates 2-5MM target patients.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "57fbc996-7b6f-402c-8435-df2fed2ce76e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.88,
        "x": 0.06,
        "y": 0.54
      },
      "kind": "quote",
      "text": "\"The biggest problem with their study was the exclusion criteria. They committed the cardinal sin, which is to cherry-pick... There's something like 24 points that would exclude diabetics from participating.\" - KOL and high volume implanter",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b687c94b-c2d8-4376-abe7-82f40df0b5cd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.88,
        "x": 0.06,
        "y": 0.34
      },
      "kind": "quote",
      "text": "\"Nevro's diabetic foot study should have taken them four months to fully recruit... They used rigid inclusion/exclusion criteria and basically have a medical monitor to pluck patients out...\" - KOL and high volume implanter",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ca23da91-a570-4c15-a41a-f51d9205feb0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "Nevro’s diabetic foot study should have taken them four months to fully recruit. ... They used rigid inclusion/exclusion criteria and basically have a medical monitor to pluck patients out saying, 'Well, that’s not outside the study but I just don’t have a good feeling about [this patient]' Doctors have called out Nevro a bunch of times for cherry-picking. — KOL and high volume implanter; The biggest problem with their study was the exclusion criteria. They committed the cardinal sin, which is to cherry-pick. — KOL and high volume implanter",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd953-3f3d-76db-b344-68f6fe6b5a32",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.88,
        "x": 0.06,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Source: https://clinicaltrials.gov/ct2/show/NCT03228420; https://www.nevro.com/English/us/investors/investor-news/investor-news-details/2019/Nevro-Announces-Completion-of-Patient-Enrollment-in-Largest-Multicenter-Randomized-Controlled-Trial-of-High-Frequency-Spinal-Cord-Stimulation-for-Painful-Diabetic-Neuropathy/default.aspx",
      "attrs": {
        "numbered": true
      },
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "94f9decc-73ca-47f2-8bc8-d23896221eba",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.88,
        "x": 0.06,
        "y": 0.09
      },
      "kind": "title",
      "text": "11. TAM expansion and growth from painful diabetic neuropathy (PDN) and other new indications are a mirage",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1b2b2809-b98c-4617-b25e-3bf77b6a0d41",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.35,
        "x": 0.06,
        "y": 0.04
      },
      "kind": "title",
      "text": "Scorpion Capital | Nevro (NYSE: NVRO)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "46ece23f-b65f-44ce-a482-e9541e083d8e",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "fraud-exposure",
      "slug": null,
      "matchId": "0e6a65c2-5c8e-4d34-860c-0e927b6b6436",
      "evidence": "The slide explicitly accuses the company of 'cherry-picking' and committing a 'cardinal sin' in study design to mislead investors.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}